Clinical Management of Lung Cancer Patients during the Outbreak of 2019 Novel Coronavirus Disease (COVID-19)

Clinical Management of Lung Cancer Patients during the Outbreak of 2019 Novel Coronavirus Disease (COVID-19)

Yan Xu, Hongsheng Liu, Ke Hu, Mengzhao WANG

Since late December 2019, an outbreak of 2019 novel coronavirus disease (COVID-19) in Wuhan, China has spread quickly nationwide. With the spread of COVID-19, the routine clinical diagnosis and treatment for lung cancer patients has been disturbed. Due to the systemic immunosuppressive of lung cancer patients caused by the malignancy and anticancer treatments, lung cancer patients are more susceptible to infection than healthy individuals. Furthermore, patients with cancer had poorer prognosis from infection. Lung cancer patients should be the priority group for COVID-19 prevention. The protection provisions and control measures aiming to protect lung cancer patients from COVID-19 have been increasingly concerned. During the COVID-19 outbreak period, it should be carefully differentiated for fever and respiratory symptoms for lung cancer patients receiving anti-tumor treatment, in order to evaluate the risk of COVID-19. Moreover, it is necessary to carry out meticulous and individualized clinical management for lung cancer patients to effectively protect the patients from COVID-19.

2020

Lung neoplasms, patient management, 2019 novel coronavirus disease

DOI: 10.3779/j.issn.1009-3419.2020.03.02

Chinese Journal of Lung Cancer

Chinese Anti-Cancer Association; Chinese Antituberculosis Association

Neoplasms. Tumors. Oncology. Including cancer and carcinogens